文献速递银屑病与炎症性皮肤病

白癜风患者使用外用钙调神经磷酸酶抑制剂与光疗后淋巴瘤及皮肤癌长期风险未增加

The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo.
PubMed 文献 · J Am Acad Dermatol · 2021-01-25

这项多中心回顾性队列研究纳入25,694例2001至2019年间接受外用钙调神经磷酸酶抑制剂或光疗≥6周的白癜风患者,随访95,203人年,观察淋巴瘤13例、光线性角化病22例、非黑色素瘤皮肤癌15例、黑色素瘤5例。外用钙调神经磷酸酶抑制剂剂量或光疗次数均未显著增加淋巴瘤和皮肤癌风险,两者联合亦未增加皮肤癌风险。

要点

  • 白癜风患者使用外用钙调神经磷酸酶抑制剂未显著增加淋巴瘤和皮肤癌长期风险。
  • 光疗次数及外用钙调神经磷酸酶抑制剂与光疗联合均未增加皮肤癌风险。
  • 研究为回顾性设计,个体随访不足4年且未校正合并症与用药史。

核心结论

  • 白癜风患者长期使用外用钙调神经磷酸酶抑制剂、光疗或两者联合均与淋巴瘤或皮肤癌风险无关联。

研究设计与样本

  • 多中心回顾性队列研究,纳入25,694例2001至2019年间接受外用钙调神经磷酸酶抑制剂或光疗≥6周的白癜风患者。
  • 确定外用钙调神经磷酸酶抑制剂累积剂量和光疗总次数,结局通过病历回顾和病理报告确认。

主要发现

  • 随访95,203人年期间,观察到淋巴瘤13例、光线性角化病22例、非黑色素瘤皮肤癌15例、黑色素瘤5例。
  • 外用钙调神经磷酸酶抑制剂剂量或光疗次数未显著增加淋巴瘤和皮肤癌风险。
  • 外用钙调神经磷酸酶抑制剂与光疗的交互作用与皮肤癌风险增加无关。

临床怎么用

  • 为白癜风患者长期使用外用钙调神经磷酸酶抑制剂和光疗的安全性提供了队列证据。

局限性

  • 回顾性研究,个体随访时间不足4年,未校正合并症和用药史。
  • 结果不能推广至其他种族。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Topical calcineurin inhibitors have been used to treat vitiligo, either alone or in combination with phototherapy; however, the long-term safety of these agents remains controversial. OBJECTIVE: To investigate the risk of lymphoma and skin cancer in vitiligo patients who received topical calcineurin inhibitors or phototherapy. METHODS: A multicenter retrospective cohort study of 25,694 vitiligo patients who received topical calcineurin inhibitors or phototherapy for 6 weeks or more between 2001 and 2019 was performed. Cumulative doses of topical calcineurin inhibitors and total phototherapy sessions were determined. Outcomes were the development of lymphoma or skin cancer after enrollment, confirmed through chart review and pathology reports. RESULTS: During 95,203 person-years, 13 cases of lymphoma, 22 of actinic keratosis, 15 of nonmelanoma skin cancer, and 5 of melanoma were observed. The risk of lymphoma and skin cancer was not significantly increased by topical calcineurin inhibitor dose or phototherapy sessions. The interaction between the topical calcineurin inhibitors and phototherapy was not associated with an increased risk of skin cancer. LIMITATIONS: Retrospective study, individual follow-up duration less than 4 years, and no adjustment for comorbidities and medication history. Not generalizable to other races. CONCLUSION: The long-term risk of skin cancer or lymphoma was not associated with the use of topical calcineurin inhibitors, phototherapy, and both treatments in combination in patients with vitiligo.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Ju HJ, Han JH, Kim MS, et al. The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo. J Am Acad Dermatol. 2021. PMID: 33508387. doi:10.1016/j.jaad.2021.01.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。